Published in Expert Opin Investig Drugs on April 01, 2005
Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci (2010) 2.40
The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol (2011) 1.39
Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs (2013) 0.96
Inhibition of human immunodeficiency virus type-1 by cdk inhibitors. AIDS Res Ther (2010) 0.92
High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase. PLoS Negl Trop Dis (2011) 0.92
Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells. PLoS One (2007) 0.90
Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res (2011) 0.89
Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements. ACS Chem Biol (2010) 0.86
An integrative model links multiple inputs and signaling pathways to the onset of DNA synthesis in hepatocytes. FEBS J (2012) 0.86
Roscovitine in cancer and other diseases. Ann Transl Med (2015) 0.86
Update on rational targeted therapy in AML. Blood Rev (2016) 0.85
A novel binding pocket of cyclin-dependent kinase 2. Proteins (2009) 0.83
A Chemical Screening Approach to Identify Novel Key Mediators of Erythroid Enucleation. PLoS One (2015) 0.80
Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines. J Biomed Sci (2015) 0.79
In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Invest New Drugs (2011) 0.78
Strong inhibition of replicative DNA synthesis in the developing rat cerebral cortex and glioma cells by roscovitine. Invest New Drugs (2009) 0.78
Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor -CR8- in mice. BMC Pharmacol Toxicol (2013) 0.78
Neuroprotection for traumatic brain injury. Handb Clin Neurol (2015) 0.77
Targeted Therapies in Adult B-Cell Malignancies. Biomed Res Int (2015) 0.76
Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Mol Cancer Ther (2016) 0.76
Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy. Bioorg Med Chem Lett (2016) 0.75
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res (2005) 2.06
Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol (2004) 1.75
Antiviral activity of CYC202 in HIV-1-infected cells. J Biol Chem (2004) 1.17
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci (2004) 1.13
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer (2010) 1.09
CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs (2003) 1.03
Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res (2006) 0.99
A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. Leuk Res (2013) 0.86
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leuk Lymphoma (2014) 0.77